Receptor mediated elevation in FABP4 levels by advanced glycation end products induces cholesterol and triacylglycerol accumulation in THP-1 macrophages

Lipids

Volumn 46, Issue 6, 2011, Pages 479-486

  Wang, Xiao Qun ^a   Yang, Ke ^a   He, Yu Song ^a   Lu, Lin ^a   Shen, Wei Feng ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Advanced glycation end products; Fatty acid binding protein 4; Lipid accumulation; Receptor for advanced glycation end products

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; BOVINE SERUM ALBUMIN; CHOLESTEROL; FATTY ACID BINDING PROTEIN 4; TRIACYLGLYCEROL;

ARTICLE; CELL LEVEL; CONTROLLED STUDY; HUMAN; HUMAN CELL; LIPID STORAGE; MACROPHAGE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

BLOTTING, WESTERN; CELL LINE, TUMOR; CHOLESTEROL; FATTY ACID-BINDING PROTEINS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MACROPHAGES; POLYMERASE CHAIN REACTION; RECEPTORS, IMMUNOLOGIC; RNA, SMALL INTERFERING; SERUM ALBUMIN, BOVINE; TRIGLYCERIDES;

EID: 79955687594     PISSN: 00244201     EISSN: 15589307     Source Type: Journal    
DOI: 10.1007/s11745-011-3542-4     Document Type: Article

References (29)

1. Kannel WB, McGee DL (1979) Diabetes and cardiovascular disease. The Framingham Study. JAMA 241:2035-2038
2. Gerrity RG, Natarajan R, Nadler JL, Kimsey T (2001) Diabetes-induced accelerated atherosclerosis in swine. Diabetes 50:1654-1665 (Pubitemid 33639607)
3. Basta G, Schmidt AM, De Caterina R (2004) Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 63:582-592 (Pubitemid 39078671)
4. Goldin A, Beckman JA, Schmidt AM, Creager MA (2006) Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 114:597-605 (Pubitemid 44199649)
5. Morigi M, Angioletti S, Imberti B, Donadelli R, Micheletti G, Figliuzzi M, Remuzzi A, Zoja C, Remuzzi G (1998) Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-kB-dependent fashion. J Clin Invest 101:1905-1915 (Pubitemid 28226110)
6. Iwashima Y, Eto M, Hata A, Kaku K, Horiuchi S, Ushikubi F, Sano H (2000) Advanced glycation end products-induced gene expression of scavenger receptors in cultured human monocyte-derived macrophages. Biochem Biophys Res Commun 277: 368-380
7. Lander HM, Tauras JM, Ogiste JS, Hori O, Moss RA, Schmidt AM (1997) Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem 272:17810-17814 (Pubitemid 27311222)
8. Burke AP, Kolodgie FD, Zieske A, Fowler DR, Weber DK, Varghese PJ, Farb A, Virmani R (2004) Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study. Arterioscler Thromb Vasc Biol 24:1266-1271 (Pubitemid 38880019)
9. Luliano L (2001) Inflammation, atherosclerosis, and coronary artery disease. Lipids 352:S41-S44
10. Hotamisligil GS, Johnson RS, Distel RJ, Ellis R, Papaioannou VE, Spiegelman BM (1996) Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science 274:1377-1379 (Pubitemid 26391462)
11. Boord JB, Maeda K, Makowski L, Babaev VR, Fazio S, Linton MF, Hotamisligil GS (2002) Adipocyte fatty acid-binding protein, aP2, alters late atherosclerotic lesion formation in severe hypercholesterolemia. Arterioscler Thromb Vasc Biol 22:1686-1691
12. Fu Y, Luo N, Lopes-Virella MF, Garvey WT (2002) The adipocyte lipid binding protein (ALBP/aP2) gene facilitates foam cell formation in human THP-1 macrophages. Atherosclerosis 165:259-269 (Pubitemid 35333352)
13. Pelton PD, Zhou L, Demarest KT, Burris TP (1999) PPARgamma activation induces the expression of the adipocyte fatty acid binding protein gene in human monocytes. Biochem Biophys Res Commun 261:456-458 (Pubitemid 29392497)
14. Fu Y, Luo N, Lopes-Virella MF (2000) Oxidized LDL induces the expression of ALBP/aP2 mRNA and protein in human THP-1 macrophages. J Lipid Res 41:2017-2023 (Pubitemid 32038997)
15. Furuhashi M, Tuncman G, Gorgun CZ, Makowski L, Atsumi G, Vaillancourt E, Kono K, Babaev VR, Fazio S, Linton MF, Sulsky R, Robl JA, Parker RA, Hotamisligil GS (2007) Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature 447:959-965 (Pubitemid 46975747)
16. Passarelli M, Tang C, McDonald TO, O'Brien KD, Gerrity RG, Heinecke JW, Oram JF (2005) Advanced glycation end product precursors impair ABCA1-dependent cholesterol removal from cells. Diabetes 54:2198-2205 (Pubitemid 40911284)
17. Isoda K, Folco EJ, Shimizu K, Libby P (2007) AGE-BSA decreases ABCG1 expression and reduces macrophage cholesterol efflux to HDL. Atherosclerosis 192:298-304 (Pubitemid 46726331)
18. Kim KA, Kim JH, Wang Y, Sul HS (2007) Pref-1 (preadipocyte factor 1) activates the MEK/extracellular signal-regulated kinase pathway to inhibit adipocyte differentiation. Mol Cell Biol 27:2294-2308 (Pubitemid 46418483)
19. Lu L, Pu LJ, Zhang Q, Wang LJ, Kang S, Zhang RY, Chen QJ, Wang JG, De Caterina R, Shen WF (2009) Increased glycated albumin and decreased esRAGE levels are related to angiographic severity and extent of coronary artery disease in patients with type 2 diabetes. Atherosclerosis 206:540-545
20. Pu LJ, Lu L, Shen WF, Zhang Q, Zhang RY, Zhang JS, Hu J, Yang ZK, Ding FH, Chen QJ, Shen J, Fang DH, Lou S (2007) Increased serum glycated albumin level is associated with the presence and severity of coronary artery disease in type 2 diabetic patients. Circ J 71:1067-1073 (Pubitemid 46998021)
21. Bucciarelli LG, Wendt T, Qu W, Lu Y, Lalla E, Rong LL, Goova MT, Moser B, Kislinger T, Lee DC, Kashyap Y, Stern DM, Schmidt AM (2002) RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 106:2827-2835 (Pubitemid 35396983)
22. Forbes JM, Yee LT, Thallas V, Lassila M, Candido R, Jandeleit- Dahm KA, Thomas MC, Burns WC, Deemer EK, Thorpe SR, Cooper ME, Allen TJ (2004) Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes 53:1813-1823
23. Tuncman G, Erbay E, Hom X, De Vivo I, Campos H, Rimm EB, Hotamisligil GS (2006) A genetic variant at the fatty acid-binding protein aP2 locus reduces the risk for hypertriglyceridemia, type 2 diabetes, and cardiovascular disease. Proc Natl Acad Sci USA 103:6970-6975
24. Furuhashi M, Fucho R, Görgün CZ, Tuncman G, Cao H, Hotamisligil GS (2008) Adipocyte/macrophage fatty acid-binding proteins contribute to metabolic deterioration through actions in both macrophages and adipocytes in mice. J Clin Invest 118:2640-2650 (Pubitemid 351949791)
25. Shaughnessy S, Smith ER, Kodukula S, Storch J, Fried SK (2000) Adipocyte metabolism in adipocyte fatty acid binding protein knockout mice (aP2-/-) after short-term high-fat feeding: functional compensation by the keratinocyte fatty acid binding protein. Diabetes 49:904-911 (Pubitemid 30349411)
26. Bahramian N, Ostergren-Lundén G, Bondjers G, Olsson U (2004) Fatty acids induce increased granulocyte macrophage-colony stimulating factor secretion through protein kinase C-activation in THP-1 macrophages. Lipids 39:243-249 (Pubitemid 38738135)
27. Goff DC Jr, Bertoni AG, Kramer H, Bonds D, Blumenthal RS, Tsai MY, Psaty BM (2006) Dyslipidemia prevalence, treatment, and control in the Multi-Ethnic Study of Atherosclerosis (MESA): gender, ethnicity, and coronary artery calcium. Circulation 113:647-656
28. Nakhjavani M, Khalilzadeh O, Khajeali L, Esteghamati A, Morteza A, Jamali A, Dadkhahipour S (2010) Serum oxidized-LDL is associated with diabetes duration independent of maintaining optimized levels of LDL-cholesterol. Lipids 45:321-327
29. Makowski L, Brittingham KC, Reynolds JM, Suttles J, Hotamisligil GS (2005) The fatty acid-binding protein, aP2, coordinates macrophage cholesterol trafficking and inflammatory activity. Macrophage expression of aP2 impacts peroxisome proliferator-activated receptor gamma and IkappaB kinase activities. J Biol Chem 280:12888-12895